FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000521707> ?p ?o ?g. }

• W2000521707 endingPage "S22" @default.
• W2000521707 startingPage "S20" @default.
• W2000521707 abstract "Highly purified porcine factor VIII:C (FVIII:C) concentrate prepared by polyelectrolyte fractionation has been available for therapeutic use since 1980. Over the last decade substantial international experience has confirmed the value of porcine FVIII:C in management of hemophilia with inhibitors, and recent studies have underlined its particular effectiveness in treating patients with the acquired form of the disease. The rationale for use of porcine FVIII:C is based on a twofold premise. First, most inhibitors interact less strongly with porcine FVIII:C than they do with the human factor; cross-reactivity is especially low, and often negligible, among patients with acquired disease. Second, when measurable levels of circulating FVIII:C can be achieved, the likelihood of clinical hemostasis is maximized. In a variable proportion of patients with the congenital disease, anamnestic rises in titers of the inhibitor against human FVIII:C may follow treatment with the porcine factor, and this phenomenon may constrain therapy. These events seem to occur rarely in persons with acquired inhibitors, however, thus broadening therapeutic application of porcine FVIII:C to these patients. Although anamnesis often is perceived as a limitation, significant untoward transfusion reactions are highly unusual after porcine FVIII:C therapy. Although early experience with this form of treatment centered on management of major bleeding episodes and hemostatic crises, use of porcine FVIII:C has more recently been extended to more routine bleeding problems, immune tolerance induction regimens, prophylaxis, and home therapy. These and other advances are discussed. Highly purified porcine factor VIII:C (FVIII:C) concentrate prepared by polyelectrolyte fractionation has been available for therapeutic use since 1980. Over the last decade substantial international experience has confirmed the value of porcine FVIII:C in management of hemophilia with inhibitors, and recent studies have underlined its particular effectiveness in treating patients with the acquired form of the disease. The rationale for use of porcine FVIII:C is based on a twofold premise. First, most inhibitors interact less strongly with porcine FVIII:C than they do with the human factor; cross-reactivity is especially low, and often negligible, among patients with acquired disease. Second, when measurable levels of circulating FVIII:C can be achieved, the likelihood of clinical hemostasis is maximized. In a variable proportion of patients with the congenital disease, anamnestic rises in titers of the inhibitor against human FVIII:C may follow treatment with the porcine factor, and this phenomenon may constrain therapy. These events seem to occur rarely in persons with acquired inhibitors, however, thus broadening therapeutic application of porcine FVIII:C to these patients. Although anamnesis often is perceived as a limitation, significant untoward transfusion reactions are highly unusual after porcine FVIII:C therapy. Although early experience with this form of treatment centered on management of major bleeding episodes and hemostatic crises, use of porcine FVIII:C has more recently been extended to more routine bleeding problems, immune tolerance induction regimens, prophylaxis, and home therapy. These and other advances are discussed." @default.
• W2000521707 created "2016-06-24" @default.
• W2000521707 creator A5032679199 @default.
• W2000521707 date "1991-11-01" @default.
• W2000521707 modified "2023-10-12" @default.
• W2000521707 title "Rationale and evolution of therapy with porcine factor VIII:C" @default.
• W2000521707 cites W2050510640 @default.
• W2000521707 cites W2413894884 @default.
• W2000521707 cites W2438513900 @default.
• W2000521707 doi "https://doi.org/10.1016/s0002-9343(91)80143-a" @default.
• W2000521707 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1746591" @default.
• W2000521707 hasPublicationYear "1991" @default.
• W2000521707 type Work @default.
• W2000521707 sameAs 2000521707 @default.
• W2000521707 citedByCount "18" @default.
• W2000521707 countsByYear W20005217072014 @default.
• W2000521707 countsByYear W20005217072022 @default.
• W2000521707 crossrefType "journal-article" @default.
• W2000521707 hasAuthorship W2000521707A5032679199 @default.
• W2000521707 hasConcept C126322002 @default.
• W2000521707 hasConcept C159654299 @default.
• W2000521707 hasConcept C203014093 @default.
• W2000521707 hasConcept C2778382381 @default.
• W2000521707 hasConcept C2778589496 @default.
• W2000521707 hasConcept C2779134260 @default.
• W2000521707 hasConcept C2779817106 @default.
• W2000521707 hasConcept C2780014101 @default.
• W2000521707 hasConcept C2781221834 @default.
• W2000521707 hasConcept C32611913 @default.
• W2000521707 hasConcept C71924100 @default.
• W2000521707 hasConcept C90924648 @default.
• W2000521707 hasConceptScore W2000521707C126322002 @default.
• W2000521707 hasConceptScore W2000521707C159654299 @default.
• W2000521707 hasConceptScore W2000521707C203014093 @default.
• W2000521707 hasConceptScore W2000521707C2778382381 @default.
• W2000521707 hasConceptScore W2000521707C2778589496 @default.
• W2000521707 hasConceptScore W2000521707C2779134260 @default.
• W2000521707 hasConceptScore W2000521707C2779817106 @default.
• W2000521707 hasConceptScore W2000521707C2780014101 @default.
• W2000521707 hasConceptScore W2000521707C2781221834 @default.
• W2000521707 hasConceptScore W2000521707C32611913 @default.
• W2000521707 hasConceptScore W2000521707C71924100 @default.
• W2000521707 hasConceptScore W2000521707C90924648 @default.
• W2000521707 hasIssue "5" @default.
• W2000521707 hasLocation W20005217071 @default.
• W2000521707 hasLocation W20005217072 @default.
• W2000521707 hasOpenAccess W2000521707 @default.
• W2000521707 hasPrimaryLocation W20005217071 @default.
• W2000521707 hasRelatedWork W1985223551 @default.
• W2000521707 hasRelatedWork W2026830088 @default.
• W2000521707 hasRelatedWork W2043132231 @default.
• W2000521707 hasRelatedWork W2058927057 @default.
• W2000521707 hasRelatedWork W2351019711 @default.
• W2000521707 hasRelatedWork W2363073319 @default.
• W2000521707 hasRelatedWork W2387103638 @default.
• W2000521707 hasRelatedWork W2909538255 @default.
• W2000521707 hasRelatedWork W3003900439 @default.
• W2000521707 hasRelatedWork W4205156913 @default.
• W2000521707 hasVolume "91" @default.
• W2000521707 isParatext "false" @default.
• W2000521707 isRetracted "false" @default.
• W2000521707 magId "2000521707" @default.
• W2000521707 workType "article" @default.